Antioxidant activity in SDG metabolites

• US 6,486,126 B1
• Filed: 06/23/2000
• Issued: 11/26/2002
• Est. Priority Date: 06/30/1999
• Status: Expired due to Term

• Current Assignee: University Of Saskatchewan
• Original Assignee: University Of Saskatchewan
• Inventors: Prasad, Kailash
• Primary Examiner(s): Riley, Jezia
• Application Number:
  US09/599,958
• Time in Patent Office: 886 Days
• Field of Search: 514/25, 514/885, 536/18.1, 424/78.08
• US Class Current: 514/25
• CPC Class Codes: A61K 31/74 Synthetic polymeric materials
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid

Abstract

The compounds secoisolariciresinol (SECO), enterodiol (ED) and enterolactone (EL), which are metabolites of secoisolariciresinol diglucoside obtained from flaxseed, are used for the treatment of diseases or conditions requiring administration of an antioxidant. Diseases or conditions that may be treated include hypercholesterolemic atherosclerosis, type I and type II diabetes, ischemic heart disease, heart failure, endotoxic and hemmorhagic shock, inflammatory bowel disease, rheumatoid arthritis, Parkinson'"'"'s disease, and stroke.

Claims

1. A method of treatment of a disease or a condition selected from the group consisting of hypercholesterolemic atherosclerosis and diabetes type I or type II, which comprises administering to a patient an effective amount of a secoisolariciresinol diglucoside (SDG) metabolite selected from the group consisting of secoisolariciresinol (SECO) enterodiol (ED) and enterolactone (EL).

2. A method according to claim 1, wherein the metabolites are used at a purity of at least 90%.

3. A method of treatment of hypercholesterolemic atherosclerosis which comprises administering to a patient an effective amount of a secoisolariciresinol diglucoside (SDG) metabolite selected from the group consisting of secoisolariciresinol (SECO) enterodiol (ED) and enterolactone (EL) at a purity of at least 90%.

4. A method of treatment of diabetes type I or type II, which comprises administering to a patient an effective amount of a secoisolariciresinol diglucoside (SDG) metabolite selected from the group consisting of secoisolariciresinol (SECO) enterodiol (ED) and enterolactone (EL) at a purity of at least 90%.